Diffusion PR

Diffusion Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies to enhance the diffusion of oxygen to hypoxic tissues, which are often resistant to conventional treatments. The company's lead product candidate, trans-sodium crocetinate (TSC), was designed to improve the effectiveness of standard-of-care treatments like radiation and chemotherapy in conditions such as glioblastoma multiforme and stroke. In August 2023, Diffusion Pharmaceuticals completed a merger with EIP Pharma, resulting in a combined company renamed CervoMed (NASDAQ: CRVO), which shifted focus toward neurodegenerative diseases. Prior to the merger, Diffusion conducted several clinical trials exploring TSC's potential in oncology and emergency medicine.